LabCorp

Recognized for our innovation, quality, and customer convenience, LabCorp delivers timely, accurate results for improved patient care. With scientific expertise in esoteric testing, genomics, and clinical and anatomic pathology, LabCorp performs more than one million tests on approximately 400,000 samples each day. LabCorp is a pioneer in applying advances in medicine and science to laboratory testing, with more than 35 years of experience in serving physicians and their patients.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

LABCORP COMMENCES CASH TENDER OFFER FOR ALL OUTSTANDING SHARES OF SEQUENOM, INC.

LabCorp | August 09, 2016

news image

BURLINGTON, N.C.--(BUSINESS WIRE)--Laboratory Corporation of America® Holdings (NYSE: LH) today announced the commencement of its cash tender offer for all outstanding shares of the common stock of Sequenom, Inc....

Read More

LABCORP ANNOUNCES THE AVAILABILITY OF THE CDC ZIKA MAC-ELISA TEST

LabCorp | August 02, 2016

news image

BURLINGTON, N.C.--(BUSINESS WIRE)--Aug. 2, 2016-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE:LH) today announced the nationwide availability of testing for Zika virus using the Zika Immunoglobulin M (IgM) Antibody Capture Enzyme-Linked Immunosorbent....

Read More

LABCORP CEO: ‘THIS IS EXACTLY THE KIND OF STRATEGIC ACQUISITION THAT LABCORP SEEKS’

LabCorp | July 27, 2016

news image

BURLINGTON, N.C. & SAN DIEGO--(BUSINESS WIRE)--Jul. 27, 2016-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE:LH), the world’s leading healthcare diagnostics company, and Sequenom, Inc....

Read More

LABCORP ANNOUNCES LAUNCH OF NEW COMPANION DIAGNOSTIC FOR NON-SMALL CELL LUNG CANCER

LabCorp | June 27, 2016

news image

The availability of this test demonstrates LabCorp’s industry-leading position in the commercialization of companion diagnostics,” said David P. King, chairman and chief executive officer of LabCorp. “The success and growth of our companion diagnostics business continues to differentiate us from our competitors as we carry out our mission to improve health and improve lives.”...

Read More
news image

LABCORP COMMENCES CASH TENDER OFFER FOR ALL OUTSTANDING SHARES OF SEQUENOM, INC.

LabCorp | August 09, 2016

BURLINGTON, N.C.--(BUSINESS WIRE)--Laboratory Corporation of America® Holdings (NYSE: LH) today announced the commencement of its cash tender offer for all outstanding shares of the common stock of Sequenom, Inc....

Read More
news image

LABCORP ANNOUNCES THE AVAILABILITY OF THE CDC ZIKA MAC-ELISA TEST

LabCorp | August 02, 2016

BURLINGTON, N.C.--(BUSINESS WIRE)--Aug. 2, 2016-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE:LH) today announced the nationwide availability of testing for Zika virus using the Zika Immunoglobulin M (IgM) Antibody Capture Enzyme-Linked Immunosorbent....

Read More
news image

LABCORP CEO: ‘THIS IS EXACTLY THE KIND OF STRATEGIC ACQUISITION THAT LABCORP SEEKS’

LabCorp | July 27, 2016

BURLINGTON, N.C. & SAN DIEGO--(BUSINESS WIRE)--Jul. 27, 2016-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE:LH), the world’s leading healthcare diagnostics company, and Sequenom, Inc....

Read More
news image

LABCORP ANNOUNCES LAUNCH OF NEW COMPANION DIAGNOSTIC FOR NON-SMALL CELL LUNG CANCER

LabCorp | June 27, 2016

The availability of this test demonstrates LabCorp’s industry-leading position in the commercialization of companion diagnostics,” said David P. King, chairman and chief executive officer of LabCorp. “The success and growth of our companion diagnostics business continues to differentiate us from our competitors as we carry out our mission to improve health and improve lives.”...

Read More